標(biāo)題: Titlebook: Decision Making in a World of Comparative Effectiveness Research; A Practical Guide Howard G. Birnbaum,Paul E. Greenberg Book 2017 Springer [打印本頁(yè)] 作者: purulent 時(shí)間: 2025-3-21 19:18
書(shū)目名稱Decision Making in a World of Comparative Effectiveness Research影響因子(影響力)
書(shū)目名稱Decision Making in a World of Comparative Effectiveness Research影響因子(影響力)學(xué)科排名
書(shū)目名稱Decision Making in a World of Comparative Effectiveness Research網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Decision Making in a World of Comparative Effectiveness Research網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Decision Making in a World of Comparative Effectiveness Research被引頻次
書(shū)目名稱Decision Making in a World of Comparative Effectiveness Research被引頻次學(xué)科排名
書(shū)目名稱Decision Making in a World of Comparative Effectiveness Research年度引用
書(shū)目名稱Decision Making in a World of Comparative Effectiveness Research年度引用學(xué)科排名
書(shū)目名稱Decision Making in a World of Comparative Effectiveness Research讀者反饋
書(shū)目名稱Decision Making in a World of Comparative Effectiveness Research讀者反饋學(xué)科排名
作者: Substance-Abuse 時(shí)間: 2025-3-21 21:21
http://image.papertrans.cn/d/image/264237.jpg作者: altruism 時(shí)間: 2025-3-22 04:22 作者: FRAUD 時(shí)間: 2025-3-22 07:00
978-981-10-9828-4Springer Nature Singapore Pte Ltd. 2017作者: languid 時(shí)間: 2025-3-22 11:36 作者: Venules 時(shí)間: 2025-3-22 15:29
Database and Expert Systems Applicationsers factors which have impacted his decision-making, how comparative effectiveness research evidence use and methodology has evolved over time, and how such evidence is strategically used within a multinational company and in interactions with diverse payers/payer systems and regulatory agencies across the world.作者: Venules 時(shí)間: 2025-3-22 19:41 作者: 含糊 時(shí)間: 2025-3-22 21:51 作者: 思考 時(shí)間: 2025-3-23 04:10 作者: progestin 時(shí)間: 2025-3-23 09:37 作者: Decibel 時(shí)間: 2025-3-23 13:25 作者: justify 時(shí)間: 2025-3-23 17:06
Ghassen Hamdi,Mohamed Nazih Omrir market access in the United States. Payers evaluate a drug’s clinical safety and effectiveness profile in relation to existing standards of care. The collected evidence is referred to here as comparative effectiveness research (CER). Augmented with evidence from cost-effectiveness and budget-impac作者: foppish 時(shí)間: 2025-3-23 20:48 作者: 表主動(dòng) 時(shí)間: 2025-3-23 23:40 作者: harangue 時(shí)間: 2025-3-24 04:59
Database and Expert Systems Applicationsbroad patient population. The recently increased emphasis on comparative effectiveness research (CER) has heightened both the level of evidence and awareness related to the potential for better targeting of treatments. However, a number of practical hurdles to implementation of such targeting by cli作者: RAFF 時(shí)間: 2025-3-24 09:33 作者: 老巫婆 時(shí)間: 2025-3-24 12:10
Lecture Notes in Computer Sciencenswer whether interventions work in real-world settings, whereas explanatory clinical trials are conducted under stricter settings with tighter control to answer whether an intervention can work. While both explanatory and pragmatic trials can have patient-centered elements, pragmatic trials more di作者: 相信 時(shí)間: 2025-3-24 16:19
Anne V. D. M. Kayem,Christoph Meinelide. CER-based evidence is key to informing the process of health technology assessment (HTA), a policy-oriented form of systematic research that aims to assess the clinical, economic, social, and ethical effect of health technologies. In many countries around the world, the results of HTA are incre作者: Merited 時(shí)間: 2025-3-24 20:43
Past Indeterminacy in Data Warehouse Designon-oncological drugs. This chapter will begin with providing an introduction to the Canadian Agency for Drugs and Technologies in Health (CADTH) and its role within the Canadian health-care system and will then describe and provide a commentary on the intricacies of the CDR process. The pathway of t作者: 威脅你 時(shí)間: 2025-3-25 00:07 作者: crutch 時(shí)間: 2025-3-25 06:56 作者: FEAS 時(shí)間: 2025-3-25 08:12
Database and Expert Systems Applicationscomparative effectiveness research (CER). He describes barriers to CER dissemination by manufacturers as well as use of CER in various litigation settings. Dr. Kalb talks about these issues with Paul Greenberg and Crystal Pike, economists at Analysis Group with whom he has worked on many legal cases作者: 翻動(dòng) 時(shí)間: 2025-3-25 13:17 作者: Instrumental 時(shí)間: 2025-3-25 18:40 作者: scotoma 時(shí)間: 2025-3-25 21:17 作者: Binge-Drinking 時(shí)間: 2025-3-26 03:05 作者: 牢騷 時(shí)間: 2025-3-26 04:31 作者: acclimate 時(shí)間: 2025-3-26 09:04
Are Real-World Data and Evidence Good Enough to Inform Health Care and Health Policy Decision-Makingnforming health-care benefit design, informing quality improvement efforts, informing health technology assessments regarding access to and pricing of new therapies, assessing the incidence/prevalence of adverse events associated with marketed medications to inform regulatory labelling, informing be作者: 巨頭 時(shí)間: 2025-3-26 13:38 作者: Salivary-Gland 時(shí)間: 2025-3-26 19:59
Decision-Making by Public Payersl that relies upon research done by the Agency for Healthcare Research and Quality. Veterans Administration is largely internally driven and closed decision-making by the clinicians and staff, but with the help of a program of their own that synthesizes evidence-based research. The Medicaid programs作者: GRIPE 時(shí)間: 2025-3-26 21:46 作者: VOK 時(shí)間: 2025-3-27 02:40 作者: Canary 時(shí)間: 2025-3-27 08:46 作者: 大洪水 時(shí)間: 2025-3-27 09:49
Evaluating Non-Pharmaceutical Technologies at the Canadian Agency for Drugs and Technologies in HealP process for priority ranking medical devices and how it differs from a pharmaceutical review, and how HTERP comes to developing their recommendations. We conclude with providing opportunities for improvement within CADTH’s device recommendations and discuss the future challenges of pushing disinve作者: Axillary 時(shí)間: 2025-3-27 17:02
Challenges and Opportunities in the Dissemination of Comparative Effectiveness Research Information ed FDAMA-114 to broaden the meaning of HCEI and loosened restrictions on the dissemination of HCEI as well as draft guidance issued by the FDA. Previously, restrictions on manufacturers’ ability to provide HCEI and other scientific information contributed to an asymmetry of information between manuf作者: 拋物線 時(shí)間: 2025-3-27 20:15
Legal Considerations in a World of Comparative Effectiveness Researche the expertise of the spokesperson may matter). In addition, they talk about managing company risk in an environment where some communications may be seen as off label and others may be seen as false or misleading. Finally, they talk about specific examples in which CER has been used effectively in作者: outrage 時(shí)間: 2025-3-27 22:03 作者: intricacy 時(shí)間: 2025-3-28 02:32
Decision Making in a World of Comparative Effectiveness Research978-981-10-3262-2作者: Accord 時(shí)間: 2025-3-28 09:23 作者: 遺傳學(xué) 時(shí)間: 2025-3-28 11:20 作者: adjacent 時(shí)間: 2025-3-28 16:35
Database and Expert Systems Applicationsnforming health-care benefit design, informing quality improvement efforts, informing health technology assessments regarding access to and pricing of new therapies, assessing the incidence/prevalence of adverse events associated with marketed medications to inform regulatory labelling, informing be作者: 遷移 時(shí)間: 2025-3-28 19:43 作者: 畢業(yè)典禮 時(shí)間: 2025-3-29 02:59
Database and Expert Systems Applicationsl that relies upon research done by the Agency for Healthcare Research and Quality. Veterans Administration is largely internally driven and closed decision-making by the clinicians and staff, but with the help of a program of their own that synthesizes evidence-based research. The Medicaid programs作者: Harpoon 時(shí)間: 2025-3-29 04:12
Lecture Notes in Computer Science trial process is one way to increase the patient-centeredness of a trial. Patients can help design recruitment and retention strategies, codevelop endpoints, review consent forms, and identify appropriate dissemination channels. Patient involvement throughout the trial benefits not only the researc作者: APRON 時(shí)間: 2025-3-29 08:20
Anne V. D. M. Kayem,Christoph Meinelnted. While England has a well-established and renowned HTA program that includes detailed CER guidelines, Japan has only recently started a two-year HTA pilot program with no CER guidelines, and the Global Fund has yet to embrace HTA practices. These three case studies serve as excellent examples o作者: 熱心助人 時(shí)間: 2025-3-29 11:31 作者: 虛構(gòu)的東西 時(shí)間: 2025-3-29 18:15
Anne V. D. M. Kayem,Christoph MeinelP process for priority ranking medical devices and how it differs from a pharmaceutical review, and how HTERP comes to developing their recommendations. We conclude with providing opportunities for improvement within CADTH’s device recommendations and discuss the future challenges of pushing disinve作者: 憤憤不平 時(shí)間: 2025-3-29 19:47
Lecture Notes in Computer Scienceed FDAMA-114 to broaden the meaning of HCEI and loosened restrictions on the dissemination of HCEI as well as draft guidance issued by the FDA. Previously, restrictions on manufacturers’ ability to provide HCEI and other scientific information contributed to an asymmetry of information between manuf作者: Ostrich 時(shí)間: 2025-3-30 02:21
Database and Expert Systems Applicationse the expertise of the spokesperson may matter). In addition, they talk about managing company risk in an environment where some communications may be seen as off label and others may be seen as false or misleading. Finally, they talk about specific examples in which CER has been used effectively in作者: 同時(shí)發(fā)生 時(shí)間: 2025-3-30 04:21 作者: 忍受 時(shí)間: 2025-3-30 11:53 作者: Cocker 時(shí)間: 2025-3-30 13:37 作者: 上腭 時(shí)間: 2025-3-30 18:34
Database and Expert Systems Applicationsrchers conducting CER and healthcare decision makers. As a whole, the vision for CER expressed in this book is one that remains optimistic in achieving its goals, where real-world studies and big data analyses are applied to meet pragmatic needs of clinicians, patients, and policymakers.作者: CRUE 時(shí)間: 2025-3-30 23:50
Perspectives of Comparative Effectiveness Research from the World of Decision Makingrchers conducting CER and healthcare decision makers. As a whole, the vision for CER expressed in this book is one that remains optimistic in achieving its goals, where real-world studies and big data analyses are applied to meet pragmatic needs of clinicians, patients, and policymakers.作者: outset 時(shí)間: 2025-3-31 03:44
Book 2017 to compare the effects of one medical treatment versus another in real world settings. While most of this burgeoning literature has focused on research findings, data and methods, Howard Birnbaum and Paul Greenberg (both of Analysis Group) have edited a book that provides a practical guide to decis作者: 眉毛 時(shí)間: 2025-3-31 07:15
Ghassen Hamdi,Mohamed Nazih Omriare seeking in new pharmaceutical products. In this chapter, we address what CER delivers in terms of information regarding the value of pharmaceutical products, to whom that information is directed, and the impact that CER can have on drug development strategy and biomedical innovation.
